A startup pioneering a 15-minute diagnostic platform for bacterial infections has raised 拢1.1 million in pre-series A investment.
FluoretiQ is developing a family of antibiotic stewardship products that identify a true and correct need for antibiotic prescription.
It says NANOPLEX provides laboratory-quality results 200 times faster than lab analysis, helping clinicians meet their targets.聽
The 15-minute assay uses glycan-based probes to find and quantify important bacterial species directly from samples.聽
FluoretiQ鈥檚 products could be an important tool in the wake of reports showing that antimicrobial resistance (AMR) is growing faster than expected.
The round was led by early-stage life science investors, Deepbridge鈥疌apital LLP, with significant participation from MAINStream, OION, SAIC and existing investors. It will enable the team at FluoretiQ to produce trial units of their first NANOPLEX product, a 15-minute UTI (urinary tract infection) diagnostic device.
鈥淩ecent headlines in the LANCET highlight the need for urgent action to get solutions to preserve the efficacy of current and future antibiotics,鈥� said FluoretiQ CEO Dr Neciah Dorh.聽
鈥淭hese funds will enable us to build cutting-edge, rapid diagnostic products that enable true antibiotic stewardship. We鈥檙e so fortunate to have a growing list of committed and visionary investors.鈥�
Angel investor, entrepreneur and medical doctor Dr Leonid Shapiro invested in FluoretiQ.
鈥淚 was impressed with both FlouretiQ鈥檚 innovation in bacterial detection and their quest to solve a much-needed problem in managing urinary infections in our nation鈥檚 elderly,鈥� he said.